Medicare Seeks Input On Dispute Resolution, Civil Penalties For Rx Pricing Program
Executive Summary
Calculating a ‘fair price’ for new versions of already negotiated moiety is also one of several that CMS is requesting input on in its recently released initial guidance on the negotiation program.
You may also be interested in...
CMS Official Calls Medicare Price Negotiations An ‘Ongoing Conversation’
The US Centers for Medicare & Medicaid Services’ Vinod Mitta discussed the agency’s latest thinking on the implementation of Medicare drug price negotiations at the Financial Times Pharma Summit.
Novo Nordisk’s Wegovy In Medicare Part D: Coverage May Not Be The Only Problem
Prospect of facing price negotiation in Part D may lead Novo Nordisk to consider earlier-than-currently-planned generic competition for its older semaglutide drug for diabetes, Ozempic.
First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands
The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.